EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
6.48
+0.57 (9.75%)
Apr 22, 2025, 4:00 PM EDT - Market closed
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for EyePoint Pharmaceuticals stock have an average target of 25.71, with a low estimate of 15 and a high estimate of 33. The average target predicts an increase of 297.07% from the current stock price of 6.48.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2025.
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +409.65% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +239.77% | Mar 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +409.65% | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +409.65% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +239.77% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
25.08M
from 43.27M
Decreased by -42.04%
Revenue Next Year
14.44M
from 25.08M
Decreased by -42.41%
EPS This Year
-2.80
from -2.32
EPS Next Year
-2.77
from -2.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.1M | 53.6M | 202.7M | ||
| Avg | 25.1M | 14.4M | 89.5M | ||
| Low | n/a | n/a | 38.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.8% | 113.5% | 1,303.0% | ||
| Avg | -42.0% | -42.4% | 519.9% | ||
| Low | - | - | 163.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.15 | -1.53 | -0.66 | ||
| Avg | -2.80 | -2.77 | -2.37 | ||
| Low | -3.08 | -3.64 | -3.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.